Saol Therapeutics: Saol Therapeutics Announces Enrollment Achievement in Pivotal Phase 3 Trial for Rare Mitochondrial Disease - Pyruvate Dehydrogenase Complex Deficiency (PDCD)
ROSWELL, Ga. and DUBLIN and HAMILTON, Bermuda, Oct. 4, 2022 /PRNewswire/ -- Saol Therapeutics, a privately held, clinical-stage pharmaceutical com...
Read full article »
Saol Therapeutics is a Georgia-based pharmaceutical company that provides therapies for CNS disorders such as pain management, spasticity, and orphan diseases.
Read more